Market Research
147 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by Robert Mcmillian
Scoop.it!

Asian Non-Knowledge based CDSS Market : ReportsnReports

Asian Non-Knowledge based CDSS Market : ReportsnReports | Market Research | Scoop.it

Check for Discount on Asian Non-Knowledge based CDSS Market report by MicroMarketMonitor. On purchase of this report, you get next three (3) quarterly...

Robert Mcmillian's insight:

Order report by calling ReportsnReports.com at +1 888 391 5441 OR send an email on sales@reportsandreports.com with (Asian Non-Knowledge based CDSS Market) / report name in subject line and your contact details.

 

On purchase of this report, you get next three (3) quarterly updates of the report for free.

The Asian non-knowledge based CDSS market was valued at $3 million in 2012, and expected to reach $3.4 million by 2018, at a CAGR of 2.4%.

The report ‘Asian Non-Knowledge based CDSS Market forecast, 2012-2018’ analyzes the market by sub-segments integrated non-knowledge based CDSS and standalone non-knowledge based CDSS. Integrated CDSS accounted for about 70% of the total market. The non-knowledge based CDSS market can also be segmented based upon components into hardware, software, and services.

The Asian market accounted for almost 7% of the total market, but is the fastest-growing market recently. Japan accounted for 35% of the global market followed by China at 30%.

The major driver for this market is the increasing demand for analytical IT solutions that helps in point-of-care decision making. The implementation of such solutions has resulted into reduction of cost and improvement in the quality of care provided. Other factors responsible for the growth of the market are the increasing government initiatives and the introduction of various incentive plans for healthcare providers.

The report also provides an extensive competitive landscaping of companies operating in this market. Meditech is the market leader followed by major players like Cerner Corporation, Athenahealth, Inc., McKesson Corporation, and Zynx Health Incorporated.

Segment and country-specific company shares, news & deals, mergers and acquisitions, segment specific pipeline products, product approvals, and product recalls of the major companies have been detailed in this report.

 

Complete report available @ http://www.reportsnreports.com/reports/313733-asian-non-knowledge-based-cdss-market.html .

 
Customization Options

Along with the market data, you can also customize MMM assessments that meet your company’s specific needs. Customize to get comprehensive industry standard and deep dive analysis of the following parameters:

Product Analysis

Usage pattern (in-depth trend analysis) of products (segment wise)Product matrix which gives a detailed comparison of product portfolio of each company mapped at country and sub-segment levelEnd-user Adoption rate analysis of the products (segment wise and country wise)

Procedure Volume Data

Number of software installedEnd-users

Surgeons/Physicians Perception Matrix

Fast turn-around analysis of surgeons’ response to market events and trendsPattern analysis of usage of devices by physiciansSurgeons’ opinion about products from different companies

Brand Perception Matrix

Comprehensive study of customers perception and behavior through our inbuilt social connect tool checking the virality and tonality of blogsAnalysis of overall brand usage and familiarity and brand advocacy distribution (detractor/neutral/familiar)

Alternative Products: Impact analysis

MMM’s healthcare decision making quadrant is an innovative and useful quadrant for vendors who wish to analyze the potential growth markets based on parameters like end user dynamics (choices, number of installations of software) and macroeconomic indicators (number of hospitals, reimbursement scenario, diagnosis rate, treatment rate and healthcare expenditure).

Purchase a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=313733 .

Table of Contents

1 Introduction
1.1 Objective of the study
1.2 Market Definitions
1.3 Market Segmentation & Aspects Covered
1.4 Research Methodology
1.4.1 Assumptions (Market Size, Forecast, etc)

2 Executive Summary

3 Market Overview

4 Non-Knowledge based CDSS-Asia, by Applications

5 Non-Knowledge based CDSS-Asia, by Deployments

6 Non-Knowledge based CDSS-Asia, by Components

7 Non-Knowledge based CDSS-Asia, by Endusers

8 Non-Knowledge based CDSS-Asia, by Products

9 Non-Knowledge based CDSS-Asia, by Geographies

10 Non-Knowledge based CDSS-Asia, by Companies

Inquire before buying this report on price $3500 @ http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=313733 .

 

About Us:

ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets. 

more...
No comment yet.
Scooped by Robert Mcmillian
Scoop.it!

European Business CVIS Market : ReportsnReports

European Business CVIS Market : ReportsnReports | Market Research | Scoop.it
Check for Discount on European Business CVIS Market report by MicroMarketMonitor. On purchase of this report, you get next three (3) quarterly...
Robert Mcmillian's insight:

Order report by calling ReportsnReports.com at +1 888 391 5441 OR send an email on sales@reportsandreports.com with (European Business CVIS Market) / report name in subject line and your contact details.

 

On purchase of this report, you get next three (3) quarterly updates of the report for free.

Business CVIS-Europe can be segmented by Components, Deployments, Companies, MacroIndicators, Endusers and Applications. Components of Business CVIS-Europe are Hardware (Healthcare IT), Software (Healthcare IT) and Services (Healthcare IT). Deployments of Business CVIS-Europe are On-premise, Web-based and Cloud-based. Companies of Business CVIS-Europe are Cerner Corporation, Allscripts, Epic Systems, McKesson Corporation, GE Healthcare, Agfa-Gevaert, Siemens AG Healthcare and Philips Healthcare. MacroIndicators of Business CVIS-Europe are Healthcare Expenditure. Endusers of Business CVIS-Europe are Office based Physicians, Hospitals, Emergency Healthcare Service providers and Nurses. Applications of Business CVIS-Europe are Clinical Guidelines, Clinical Reminders, Drug-Drug Interactions, Drug Allergy Alerts and Drug Dosing Support.

 

Complete report available @ http://www.reportsnreports.com/reports/313551-european-business-cvis-market.html .

Table of Contents

1 Introduction
1.1 Introduce the Market
1.2 Objective of the study
1.3 Market Definition and Scope of the study
1.3.1 Market Definition
1.3.2 Areas covered
1.3.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Secondary sources
1.5.2 Primary Sources
1.5.3 Market estimation methodology (Top-down, bottom-up, data triangulation.)
1.5.4 Macro indicators for the study
1.6 Assumptions
1.7 List of Acronyms

2 Market Overview

3 Business CVIS-Europe, By Applications
3.1 Split By Geography
3.2 Business CVIS-Europe-Clinical Guidelines
3.2.1 Business CVIS-Europe-Clinical Guidelines, By Geographies
3.2.1.1 Business CVIS-United Kingdom-Clinical Guidelines
3.2.1.2 Business CVIS-France-Clinical Guidelines
3.2.1.3 Business CVIS-Germany-Clinical Guidelines
3.2.1.4 Business CVIS-Italy-Clinical Guidelines
3.2.1.5 Business CVIS-Spain-Clinical Guidelines
3.2.1.6 Business CVIS-Europe - Europe - Other Geographies-Clinical Guidelines
3.2.2 Business CVIS-Europe-Clinical Guidelines, By Products
3.2.2.1 Integrated Business CVIS-Europe-Clinical Guidelines
3.2.2.2 Standalone Business CVIS-Europe-Clinical Guidelines
3.3 Business CVIS-Europe-Clinical Reminders

Purchase a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=313551 .

4 Business CVIS-Europe, By Components
4.1 Split By Geography
4.2 Business CVIS-Europe-Hardware (Healthcare IT)
4.2.1 Business CVIS-Europe-Hardware (Healthcare IT), By Geographies

5 Business CVIS-Europe, By Deployments
5.1 Split By Geography
5.2 Business CVIS-Europe-On-premise
5.2.1 Business CVIS-Europe-On-premise, By Geographies
5.2.1.1 Business CVIS-United Kingdom-On-premise

6 Business CVIS-Europe, By Endusers
6.1 Split By Geography
6.2 Business CVIS-Europe-Office based Physicians
6.2.1 Business CVIS-Europe-Office based Physicians, By Geographies
6.2.1.1 Business CVIS-United Kingdom-Office based Physicians
6.2.1.2 Business CVIS-France-Office based Physicians

7 Business CVIS-Europe, By Products
7.1 Split By Geography
7.2 Integrated Business CVIS-Europe
7.2.1 Integrated Business CVIS-Europe, By Components
7.2.1.1 Integrated Business CVIS-Europe-Hardware (Healthcare IT)

Inquire before this report on price $3500 @ http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=313551 .

 

About Us:

ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets. 

more...
No comment yet.
Scooped by Robert Mcmillian
Scoop.it!

European Departmental PACS Industry Worth $1051 million by 2018

European Departmental PACS Industry Worth $1051 million by 2018 | Market Research | Scoop.it

Check for Discount on European Departmental PACS Market Research Report report by MicroMarketMonitor. On purchase of this report, you get next three (3) quarterly...

Robert Mcmillian's insight:

Order report by calling ReportsnReports.com at +1 888 391 5441 OR send an email on sales@reportsandreports.com with (European Departmental PACS Market Research Report) / report name in subject line and your contact details.

 

On purchase of this report, you get next three (3) quarterly updates of the report for free.

The European Departmental Picture Archiving and Communication System (PACS) Market was valued at $776 million in 2012 and is expected to reach $1051 million by 2018, at a CAGR of 5.18%.

The report “European Departmental Picture Archiving and Communication System Market forecast, 2012-2018” analyzes the market on the basis of components, delivery modes, imaging modalities and application types. In the delivery mode segment, on-premise forms the largest segment of the overall market, as on premise delivery mode is perceived to offer better control and secure sharing of data.

Europe is the second largest world player in Departmental Picture Archiving and Communication System (PACS) Market at 27%. Germany holds 25%, while France adds up to 20% of the European Departmental Picture Archiving and Communication System (PACS) Market.

Departmental Picture Archiving and Communication Systems (PACS) have reduced the physical and time barriers associated with traditional film-based image retrieval, distribution, and display. Departmental Picture Archiving and Communication System (PACS) has widespread application in hospitals and clinics as it eliminates the need of maintaining hard copies of images and replaces them with digital storage. Cloud based PACS solutions is the latest market development which is expected to take a significant market share in the next 5 years.

The Departmental Picture Archiving and Communication System (PACS) market report provides an extensive competitive landscaping of companies operating in this market. GE Healthcare (U.K.) is the market leader followed by major players like McKesson Corporation, Philips Healthcare (The Netherlands), Agfa HealthCare (Belgium), Siemens Healthcare (Germany), Carestream Health (U.S.), Fujifilm Corporation (Japan).

Segment and country specific Company shares, News & Deals, M&A, segment specific pipeline products, product approvals and product recalls of the major companies have been detailed.

Complete report available @ http://www.reportsnreports.com/reports/313867-european-departmental-pacs-market-research-report.html .

Customization Options:

Along with the market data, you can also customize MMM assessments that meet your company’s specific needs. Customize to get comprehensive industry standards and deep dive analysis of the following parameters:

Product Analysis

Usage pattern (in-depth trend analysis) of products (Segment wise)Product Matrix which gives a detailed comparison of product portfolio of each company mapped at country and sub segment levelEnd-user Adoption rate analysis of the products (Segment wise and Country wise)

Procedure Volume Data

Number of software installedEnd users

Brand Perception Matrix

Comprehensive study of customers perception and behavior through our inbuilt social connect tool checking the virality and tonality of blogsAnalysis of overall brand usage and familiarity and brand advocacy distribution (Detractor/Neutral/Familiar)

 

Purchase a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=313867 .

Table of Contents

1 Introduction
1.1 Objective of the study
1.2 Market Definitions
1.3 Market Segmentation & Aspects Covered
1.4 Research Methodology
1.4.1 Assumptions (Market Size, Forecast, etc)

2 Executive Summary

3 Market Overview

4 Departmental PACS-Europe, By Types
4.1 Radiology PACS-Europe
4.2 Cardiology PACS-Europe

Inquire for Discount on price $3500 @ http://www.reportsnreports.com/contacts/discount.aspx?name=313867 .

 

About Us:

ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets. 

more...
No comment yet.
Scooped by Robert Mcmillian
Scoop.it!

Asian Ophthalmology Diagnostic and Monitoring Devices Industry Worth $533.2 million by 2018

Asian Ophthalmology Diagnostic and Monitoring Devices Industry Worth $533.2 million by 2018 | Market Research | Scoop.it

Check for Discount on Asian Ophthalmology Diagnostic and Monitoring Devices Market report by MicroMarketMonitor. On purchase of this report, you get next three (3) quarterly...

Robert Mcmillian's insight:

Order report by calling ReportsnReports.com at +1 888 391 5441 OR send an email on sales@reportsandreports.com with (Asian Ophthalmology Diagnostic and Monitoring Devices Market) / report name in subject line and your contact details.

On purchase of this report, you get next three (3) quarterly updates of the report for free

The Asian ophthalmology diagnostic and monitoring devices market is mainly driven by an increase in the incidences and prevalence of ophthalmic disorders with a rapid increase in population.

The Asian market for ophthalmology diagnostic and monitoring devices was valued at $341.5 million in 2013, and expected to reach $533.2 million by 2018. It is projected to grow at a CAGR of 9.2% for the period 2013 to 2018. The ‘Fundus Camera’ market is the largest product segment in this market, with a value of $94.3 million in 2013.

The report on the Asian ophthalmology diagnostic and monitoring devices market analyzes the products under various types, namely optical coherence tomographers, ophthalmic ultrasound imaging systems, fundus cameras, ophthalmoscopes, retinoscopes, wavefront abberometers, corneal topographers, autorefractors/phoropters, pachymeters, keratometers, and specular microscopes. The product fundus camera is further segmented into products including non-mydriatic, mydriatic, and non-mydriatic/mydriatic.

In Asian countries like China and India, the rapidly growing population has been offering significant opportunities to the device manufacturers giving an impetus to this industry.

Complete report available @ http://www.reportsnreports.com/reports/313841-asian-ophthalmology-diagnostic-and-monitoring-devices-market.html .

There were around 110 million people suffering from diabetic retinopathy in 2011. This is projected to reach 180 million by 2030. There are more than 175 million individuals in the world who are blind or at a serious risk of becoming blind, according to the World Health Organization. Changing demographics also present considerable opportunities for the Asian ophthalmology diagnostic and monitoring devices market.

This report also provides an extensive competitive landscape of companies operating in this market. The main companies extensively covered in this report are Topcon, Carl Zeiss, and Nidek. Other companies like Optovue, Optopol Technology, OPKO Health, Inc., Haag-Streit AG, Ziemer Ophthalmic Systems AG, and Tomey Corporation account for 38% of the total ophthalmology diagnostic and monitoring devices market.

Segment and country-specific company shares, news and deals, mergers and acquisitions, segment-specific pipeline products, product approvals, and product recalls of major companies have been detailed in this report.

Purchase a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=313841 .

Customization Options

Along with the market data, you can also customize MMM assessments that meet your company’s specific needs. Customize your report on the Asian market for ophthalmology diagnostic and monitoring devices to get an insight into all-inclusive industry standards and a deep-dive analysis of the following considerations:

Product Analysis

Usage pattern (in-depth trend analysis) of products (segment wise) of ophthalmology surgery devicesProduct matrix which gives a detailed comparison of the product portfolio of each company mapped at country and sub-segment levelEnd-user adoption rate analysis of the products (segment wise and country wise)

Epidemiology Data

Country-specific prevalence of cataract, glaucoma, and diabetic retinopathyCountry-specific incidences of cataract, glaucoma, and diabetic retinopathyDisease progression (pattern analysis)

Procedure Volume Data

Number of surgical procedures performed for cataract, glaucoma, and corneal transplants in each country

Brand/Product Perception Matrix

Comprehensive study of customer perception and behavior through our inbuilt social connect tool checking the virality and tonality of blogsAnalysis of overall brand usage and familiarity and brand advocacy distribution (detractor/neutral/familiar)

Competitive Intelligence

Market share analysis of the top players in the marketCrucial developments and strategies companies are implementing in order to grow

Inquire for Discount on price $3500 @ http://www.reportsnreports.com/contacts/discount.aspx?name=313841 .

About Us:

ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets. 

 
more...
No comment yet.
Scooped by Robert Mcmillian
Scoop.it!

Asian Trauma Fixation Devices Market Research Report : ReportsnReports

Asian Trauma Fixation Devices Market Research Report : ReportsnReports | Market Research | Scoop.it
Check for Discount on Asian Trauma Fixation Devices Market Research Report report by MicroMarketMonitor. On purchase of this report, you get next three (3) quarterly...
Robert Mcmillian's insight:

New Market Research Report on “Asian Trauma Fixation Devices Market Research Report” added to ReportsnReports.com.

On purchase of this report, you get next three (3) quarterly updates of the report for free.

The Asian Trauma Fixation Devices Market is mainly driven by increasing prevalence of osteoporosis and increasing incidences of accidental fracture.

The report “The Asian Trauma Fixation Devices Market forecast, 2012-2018” analyzes the market of devices by 2 segments Internal Fixator Devices and External Fixator Devices.  Both segments experienced positive growth till 2012 with an increased awareness for procedures and sophisticated diagnostic techniques.

Increasing incidences of osteoporosis is the main cause for fractures, especially for wrist, spine, and hip. This is one of the reasons for driving the demand for trauma fixation devices market. The incidences of osteoporosis-related fractures are higher for women than men. The sedentary lifestyle and obesity is the major cause of trauma related injuries.

Internal fixator market is by far the largest market as these devices have well proven track records for trauma fixation and are more effective than the external devices. Moreover these devices are used for permanent solution to support broken bone, contrary to external devices which are used on temporary basis.

Major driver for the growth of internal fixation devices is advancements in product technologies and designs, along with the use of various new, efficient constituent materials including stainless steel, titanium, and bio-absorbable materials such as polyamide and carbon polymers. This report also provides an extensive competitive landscaping of companies operating in this market.

 Complete report available @ http://www.reportsnreports.com/reports/313586-asian-trauma-fixation-devices-market-research-report.html .

Osteoporosis and huge number of accident cases due to automobile-related mishaps is the major driver for this market in Asia and the market is destined to retain the pole position in the coming years also.

Geographically, The Asian Trauma Fixation Devices Market is divided into India, China, Japan and Rest of Asia.

The main companies operating in Orthopedic Accessories Systems Market and extensively covered in this report are Biomet, DePuy, Stryker, and Smith & Nephew.

Customization Options:

Along with the market data, you can also customize MMM assessments that meet your Company’s specific needs. Customize to get comprehensive industry standard and deep dive analysis of the following parameters:

Product Analysis

Usage pattern (in-depth trend analysis) of products (Segment wise)Product Matrix which gives a detailed comparison of product portfolio of each company mapped at country and sub segment levelEnd-user Adoption rate analysis of the products (Segment wise and Country wise)Comprehensive coverage of Product approvals, Pipeline products and Product recalls

Epidemiology Data

Country specific Incidence of trauma cases

Procedure Volume Data

The global population is affected by osteoporosisNumber of the hip and knee fracture in the elderly population found  in each country

Surgeons/Physicians Perception Analysis

Fast turn-around analysis of Surgeons response to market events and trendsPattern analysis of usage of Internal Fixator Devices (antibiotic and non-antibiotic) by PhysiciansSurgeons opinion about products from different companiesSurgeons qualitative inputs on epidemiology data

Brand/Product Perception Matrix

Comprehensive study of customers perception and behavior through our inbuilt social connect tool checking the virality and tonality of blogsAnalysis of overall brand usage and familiarity and brand advocacy distribution (Detractor/Neutral/Familiar)

Alternative Products: Impact analysis

MMM’s Healthcare Decision Making Quadrant It is an innovative and useful quadrant for vendors who wish to analyze the potential growth markets based on parameters like Patient dynamics (Patient pool, epidemiology of disease, preference towards surgeries/alternative therapies) and Macroeconomic indicators (Number of Hospitals and Orthopedic clinics, reimbursement scenario, diagnosis rate, treatment rate and healthcare expenditure)

Purchase a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=313586 .

Table of Contents

1 Introduction
1.1 Objective of the study
1.2 Market Definitions
1.3 Market Segmentation & Aspects Covered
1.4 Research Methodology
1.4.1 Assumptions (Market Size, Forecast, etc)

2 Executive Summary

3 Market Overview

4 Fixation Devices-Asia, By Segments
4.1 Split By Geography
4.1 Trauma Fixation Devices-Asia - Japan by Markets
4.1 Trauma Fixation Devices-China by Markets
4.1 Trauma Fixation Devices-India by Markets
4.2 Internal Fixator Devices-Asia
4.2.1 Internal Fixator Devices-Asia, By Endusers
4.2.1.1 Internal Fixator Devices-Asia-Hospitals
4.2.1.2 Internal Fixator Devices-Asia-Point of Care Testing
4.2.1.3 Internal Fixator Devices-Asia-Other Endusers
4.2.2 Internal Fixator Devices-Asia, By Geographies

Inquire for Discount on price $3500 @ http://www.reportsnreports.com/contacts/discount.aspx?name=313586 .

About Us:

ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets. 

 
more...
No comment yet.
Scooped by Robert Mcmillian
Scoop.it!

Molecular Partners AG – Product Pipeline Review – 2014

Molecular Partners AG – Product Pipeline Review – 2014 | Market Research | Scoop.it
Molecular Partners AG - Product Pipeline Review - 2014 is a market research report available at US $1500 for a Single User PDF License from RnR Market Research Reports Library.
Robert Mcmillian's insight:

The report “Molecular Partners AG – Product Pipeline Review – 2014” is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with report name in subject line and your contact details to purchase this report or get your questions answered.

Summary

Researcher’s, Molecular Partners AG – Product Pipeline Review – 2014′, provides an overview of the Molecular Partners AG’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Molecular Partners AG’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Researcher’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Researcher’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Researcher’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Complete report is available @ http://www.rnrmarketresearch.com/molecular-partners-ag-product-pipeline-review-2014-market-report.html .

Scope

- The report provides brief overview of Molecular Partners AG including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Molecular Partners AG’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Molecular Partners AG’s pipeline products

Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=235063 .

Reasons to Buy

- Evaluate Molecular Partners AG’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Molecular Partners AG in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Molecular Partners AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Molecular Partners AG and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Molecular Partners AG
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Molecular Partners AG and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 

Inquire before buying this report @ http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=235063 . (Single User License : US$ 1500 And Corporate User License : US$ 4500)

For further information on “Molecular Partners AG – Product Pipeline Review – 2014” report OR for any other business research / market intelligence need contact sales@rnrmarketresearch.com  / Call +1 888 391 5441.

more...
No comment yet.
Scooped by Robert Mcmillian
Scoop.it!

Irritable Bowel Syndrome Therapeutics Industry Pipeline Review, H2 2014

Irritable Bowel Syndrome Therapeutics Industry Pipeline Review, H2 2014 | Market Research | Scoop.it

Irritable Bowel Syndrome - Pipeline Review, H2 2014 is a market research report available at US $2000 for a Single User PDF License from RnR Market Research Reports Library.

Robert Mcmillian's insight:

The report “Irritable Bowel Syndrome – Pipeline Review, H2 2014” is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with report name in subject line and your contact details to purchase this report or get your questions answered.

Summary

Researcher’s, Irritable Bowel Syndrome – Pipeline Review, H2 2014′, provides an overview of the Irritable Bowel Syndrome’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects.

Researcher’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Researcher’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Researcher’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Complete report is available @ http://www.rnrmarketresearch.com/irritable-bowel-syndrome-pipeline-review-h2-2014-market-report.html .

Scope

- The report provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Irritable Bowel Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Irritable Bowel Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Irritable Bowel Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=235038 .

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Irritable Bowel Syndrome
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Irritable Bowel Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Inquire before buying this report @ http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=235038 . (Single User License : US$ 2000 And Corporate User License : US$ 6000)

For further information on “Irritable Bowel Syndrome – Pipeline Review, H2 2014” report OR for any other business research / market intelligence need contact sales@rnrmarketresearch.com  / Call +1 888 391 5441.

more...
No comment yet.
Scooped by Robert Mcmillian
Scoop.it!

The Global Pre-Filled Syringe Industry to 2024 - Key Trends and Growth Opportunities

The Global Pre-Filled Syringe Industry to 2024 - Key Trends and Growth Opportunities | Market Research | Scoop.it

[125 Pages Report] Check for Discount on The Global Pre-Filled Syringe Market to 2024 report by GMR Data Ltd. The Global Pre-filled Syringe Market 2014-2024 report analys...

Robert Mcmillian's insight:

Order report by calling ReportsnReports.com at +1 888 391 5441 OR send an email on sales@reportsandreports.com with (The Global Pre-Filled Syringe Market to 2024) / report name in subject line and your contact details.

 

The Global Pre-filled Syringe Market 2014-2024 report analyses how this important sub-sector will continue to grow across the next decade. The report highlights key companies, geographies and products that we believe will deliver double digit growth across the next decade.

Buy this report today and acquire analysis of the state of the pre-filled syringes market in 2014 and a market forecastfor the period 2014-2024. Market forecasts are also provided for global pre-filled syringes for glass and plastics on the global level (value and volume) as well as for the geographic regions of key pre-filled syringe types (value and volume).

The advantages that will drive the growth of pre-filled syringes include ease of administration, improved safety, reduced risk of contamination, elimination of medication errors, low incidence of needlestick injuries, accurate dosing and reduction in medical expenditure due to reduced visits to healthcare facilities.

Complete report is available @ http://www.reportsnreports.com/reports/313404-the-global-pre-filled-syringe-market-to-2024.html .

 

When compared to standard injectables, the pre-filled syringes market is still evolving, and its use is slowly increasing. Developed countries have shown a strong adoption rate for pre-filled syringes whereas developing & ROW countries have often been slow in adopting this technology. During the forecast period, however, the adoption rate will witness a healthy growth in emerging markets, and will witness a growth rate above that of developed geographies such as the US and in Europe.

The market is highly consolidated and is currently dominated by key global players such as Abbott Labs, Becton Dickinson, Baxter, Nipro Corporation, Schott, Gerresheimer, West Pharmaceutical, Ypsomed, Bespak and Unilife Corporation. Other companies such as Haselmeier; Weigao Group, Nuova Ompi (Stevanato Group), Owen Mumford and Vetter Pharma are likely to foster innovation in the coming years.

The Global Pre-filled Syringe Market 2014-2024 report includes over 125 tables, charts and graphs quantifying and forecasting the market in detail. In addition, the report offers 14 profiles of the leading PFS companies in the market alongside 3 expert interviewees offering key insights into the state of the market currently and in the future;

Schott KaisaWest PharmaceuticalsFresenius Kabi

Buy a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=313404 .

List of Companies

Abbott LabsAbbVieAesicaAesRX LLC (Part of Baxter International)AmgenAntares Pharma Inc.BauschBaxterBayerBecton DickinsonBerlin-ChemieBioconBiogen IdecBiogen Inc.Biosensors International GroupBMSBoehringer IngelheimBracco Diagnostics Inc.Carl Zeiss FoundationCato Software Solutions (Part of BD)CB Medical Holdings LimitedCell Science & Technology Institute (Part of Nipro Corporation)CelltrionCoherusContract Development and Manufacturing Organisation (CDMO)Daiichi SanyoDeveloping Countries Vaccine Manufacturers Network (DCVMN)Dong-A PharmaceuticalEgisEli LillyEuropean Medicines Agency (EMA)European Union (EU)Ferring PharmaceuticalsFood and Drug Administration (FDA)Gambro AB (Part of Baxter International)GenentechGeneScience PharmaceuticalsGenzymeGerresheimerGlaxoSmithKlineGlobe Medical TechHaselmeierHospiraHyaluron Contract manufacturingInternational Federation of Pharmaceutical Manufacturers and Association (IFPMA)ItochuJohnson & JohnsonKapoor Glass

 

Inquire before buying this report @ http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=313404 .

 

(For Single User License: US$ 2500)

 

 

 

Contact sales@reportsandreports.com / Call +1 888 391 5441 for further information on “The Global Pre-Filled Syringe Market to 2024” report OR for any other market research and intelligence needs you may have for your business.

 

 

more...
No comment yet.
Scooped by Robert Mcmillian
Scoop.it!

Metastatic Melanoma Therapeutics Industry Pipeline Review, H2 2014

Metastatic Melanoma - Pipeline Review, H2 2014 is a market research report available at US $2000 for a Single User PDF License from RnR Market Research Reports Library.

Robert Mcmillian's insight:

The report “Metastatic Melanoma – Pipeline Review, H2 2014” is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with report name in subject line and your contact details to purchase this report or get your questions answered.

Summary

Researcher’s, ‘Metastatic Melanoma – Pipeline Review, H2 2014′, provides an overview of the Metastatic Melanoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects.

Researcher’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Researcher’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Researcher’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Complete report is available @ http://www.rnrmarketresearch.com/metastatic-melanoma-pipeline-review-h2-2014-market-report.html .

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Melanoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Metastatic Melanoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Metastatic Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Melanoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=235017 .

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Inquire before buying this report @ http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=235017 . (Single User License : US$ 2000 And Corporate User License : US$ 6000)

For further information on “Metastatic Melanoma – Pipeline Review, H2 2014” report OR for any other business research / market intelligence need contact sales@rnrmarketresearch.com  / Call +1 888 391 5441.

more...
No comment yet.
Scooped by Robert Mcmillian
Scoop.it!

Multiple Sclerosis Therapeutics Industry Pipeline Review, H2 2014

Multiple Sclerosis Therapeutics Industry Pipeline Review, H2 2014 | Market Research | Scoop.it

Multiple Sclerosis - Pipeline Review, H2 2014 is a market research report available at US $2500 for a Single User PDF License from RnR Market Research Reports Library.

Robert Mcmillian's insight:

The report “Multiple Sclerosis – Pipeline Review, H2 2014” is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with report name in subject line and your contact details to purchase this report or get your questions answered.

Summary

Researcher’s, Multiple Sclerosis Pipeline Review, H2 2014′, provides an overview of the Multiple Sclerosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Multiple Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Sclerosis and special features on late-stage and discontinued projects.

Researcher’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Researcher’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Researcher’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Multiple sclerosis is the most common autoimmune disorder affecting the central nervous system. As of 2008, between 2 and 2.5 million people are affected globally with rates varying widely in different regions of the world and among different populations. The disease usually begins between the ages of 20 and 50 and is twice as common in women as in men. The name multiple sclerosis refers to scars (sclerae—better known as plaques or lesions) in particular in the white matter of the brain and spinal cord. MS was first described in 1868 by Jean-Martin Charcot. A number of new treatments and diagnostic methods are under development.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Complete report is available @ http://www.rnrmarketresearch.com/multiple-sclerosis-pipeline-review-h2-2014-market-report.html .

Scope

The report provides a snapshot of the global therapeutic landscape of Multiple SclerosisThe report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activitiesThe report reviews key players involved in the therapeutics development for Multiple Sclerosis and enlists all their major and minor projectsThe report summarizes all the dormant and discontinued pipeline projectsA review of the Multiple Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sourcesPipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stagesA detailed assessment of monotherapy and combination therapy pipeline projectsCoverage of the Multiple Sclerosis pipeline on the basis of target, MoA, route of administration and molecule typeLatest news and deals relating related to pipeline products

Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=235011 .

Reasons to Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantageDevelop strategic initiatives by understanding the focus areas of leading companiesIdentify and understand important and diverse types of therapeutics under development for Multiple SclerosisPlan mergers and acquisitions effectively by identifying key players of the most promising pipelineDevise corrective measures for pipeline projects by understanding Multiple Sclerosis pipeline depth and focus of Indication therapeuticsDevelop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeModify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Inquire for discount on this report @ http://www.rnrmarketresearch.com/contacts/discount?rname=235011 . (Single User License : US$ 2500 And Corporate User License : US$ 7500)

For further information on “Multiple Sclerosis – Pipeline Review, H2 2014” report OR for any other business research / market intelligence need contact sales@rnrmarketresearch.com  / Call +1 888 391 5441.

more...
No comment yet.
Scooped by Robert Mcmillian
Scoop.it!

Major Depressive Disorder Therapeutics – Pipeline Market Review, H2 2014

Major Depressive Disorder Therapeutics – Pipeline Market Review, H2 2014 | Market Research | Scoop.it

Major Depressive Disorder - Pipeline Review, H2 2014 is a market research report available at US $2000 for a Single User PDF License from RnR Market Research Reports Library.

Robert Mcmillian's insight:

The report “Major Depressive Disorder – Pipeline Review, H2 2014” is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with report name in subject line and your contact details to purchase this report or get your questions answered.


Summary

Researcher’s, ‘Major Depressive Disorder Pipeline Review, H2 2014′, provides an overview of the Major Depressive Disorder’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Major Depressive Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Major Depressive Disorder and special features on late-stage and discontinued projects.

 

Researcher’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Researcher’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Researcher’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

 

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Complete report is available @ http://www.rnrmarketresearch.com/major-depressive-disorder-pipeline-review-h2-2014-market-report.html .


Scope

The report provides a snapshot of the global therapeutic landscape of Major Depressive DisorderThe report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activitiesThe report reviews key players involved in the therapeutics development for Major Depressive Disorder and enlists all their major and minor projectsThe report summarizes all the dormant and discontinued pipeline projectsA review of the Major Depressive Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sourcesPipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stagesA detailed assessment of monotherapy and combination therapy pipeline projectsCoverage of the Major Depressive Disorder pipeline on the basis of target, MoA, route of administration and molecule typeLatest news and deals relating related to pipeline products

Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=203951 .


Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantageDevelop strategic initiatives by understanding the focus areas of leading companiesIdentify and understand important and diverse types of therapeutics under development for Major Depressive DisorderPlan mergers and acquisitions effectively by identifying key players of the most promising pipelineDevise corrective measures for pipeline projects by understanding Major Depressive Disorder pipeline depth and focus of Indication therapeuticsDevelop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeModify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Inquire before buying this report @ http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=203951 . (Single User License : US$ 2000 And Corporate User License : US$ 6000)


For further information on “Major Depressive Disorder – Pipeline Review, H2 2014” report OR for any other business research / market intelligence need contact sales@rnrmarketresearch.com  / Call +1 888 391 5441.

more...
No comment yet.
Scooped by Robert Mcmillian
Scoop.it!

Ewing Sarcoma – Pipeline Industry Review, H2 2014

Ewing Sarcoma – Pipeline Industry Review, H2 2014 | Market Research | Scoop.it

Ewing Sarcoma - Pipeline Review, H2 2014 is a market research report available at US $2000 for a Single User PDF License from RnR Market Research Reports Library.

Robert Mcmillian's insight:

The report “Ewing Sarcoma – Pipeline Review, H2 2014” is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with report name in subject line and your contact details to purchase this report or get your questions answered.


Summary

Researcher’s, Ewing Sarcoma Pipeline Review, H2 2014′, provides an overview of the Ewing Sarcoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ewing Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ewing Sarcoma and special features on late-stage and discontinued projects.

 

Researcher’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Researcher’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Researcher’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Complete report is available @ http://www.rnrmarketresearch.com/ewing-sarcoma-pipeline-review-h2-2014-market-report.html .


Scope

The report provides a snapshot of the global therapeutic landscape of Ewing SarcomaThe report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activitiesThe report reviews key players involved in the therapeutics development for Ewing Sarcoma and enlists all their major and minor projectsThe report summarizes all the dormant and discontinued pipeline projectsA review of the Ewing Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sourcesPipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stagesA detailed assessment of monotherapy and combination therapy pipeline projectsCoverage of the Ewing Sarcoma pipeline on the basis of target, MoA, route of administration and molecule typeLatest news and deals relating related to pipeline products

Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=201672 .


Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantageDevelop strategic initiatives by understanding the focus areas of leading companiesIdentify and understand important and diverse types of therapeutics under development for Ewing SarcomaPlan mergers and acquisitions effectively by identifying key players of the most promising pipelineDevise corrective measures for pipeline projects by understanding Ewing Sarcoma pipeline depth and focus of Indication therapeuticsDevelop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeModify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Inquire before buying this report @ http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=201672  . (Single User License : US$ 2000 And Corporate User License : US$ 6000)


For further information on “Ewing Sarcoma – Pipeline Review, H2 2014” report OR for any other business research / market intelligence need contact sales@rnrmarketresearch.com  / Call +1 888 391 5441.

more...
No comment yet.
Scooped by Robert Mcmillian
Scoop.it!

Brazil Hyperbaric Oxygen Chambers Industry Analysis and Forecast to 2020

Brazil Hyperbaric Oxygen Chambers Industry Analysis and Forecast to 2020 | Market Research | Scoop.it

Brazil Hyperbaric Oxygen Chambers Market Outlook to 2020 is a market research report available at US $2500 for a Single User PDF License from RnR Market Research Reports Library.

Robert Mcmillian's insight:

The report “Brazil Hyperbaric Oxygen Chambers Market Outlook to 2020” is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with report name in subject line and your contact details to purchase this report or get your questions answered.

Summary

Researcher’s new report, “Brazil Hyperbaric Oxygen Chambers Market Outlook to 2020″, provides key market data on the Brazil Hyperbaric Oxygen Chambers market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments Hyperbaric Oxygen Chambers (Monoplace and Multiplace Hyperbaric Oxygen Chambers).

The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Hyperbaric Oxygen Chambers market wherever available.

The data in the report is derived from dynamic market forecast models. Researcher uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible.

The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers.

Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases).

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Complete report is available @ http://www.rnrmarketresearch.com/brazil-hyperbaric-oxygen-chambers-market-outlook-to-2020-market-report.html .

Scope

Market size data for Hyperbaric Oxygen Chambers market segments Hyperbaric Oxygen Chambers.Annualized market revenues (USD million), volume (units) and average prices (in US dollars) data for each of the market segments. Data is provided from 2005 to 2013 and forecast to 2020.2013 company shares and distribution shares data for Hyperbaric Oxygen Chambers market.Global corporate-level profiles of key companies operating within the Brazil Hyperbaric Oxygen Chambers.Key players covered include Seaway Diver and Sechrist Industries Inc.

Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=233894 .

Reasons to buy

Develop business strategies by identifying the key market categories and segments poised for strong growth in the future.Develop market-entry and market expansion strategies.Design competition strategies by identifying who-stands-where in the market.Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.What are the key distribution channels and what’s the most preferred mode of product distribution Identify, understand and capitalize.

 

Inquire for Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=233894 . (Single User License : US$ 2500 And Corporate User License : US$ 7500)

For further information on “Brazil Hyperbaric Oxygen Chambers Market Outlook to 2020” report OR for any other business research / market intelligence need contact sales@rnrmarketresearch.com  / Call +1 888 391 5441.

more...
No comment yet.
Scooped by Robert Mcmillian
Scoop.it!

European Computerized Physician Order Entry Market : ReportsnReports

European Computerized Physician Order Entry Market : ReportsnReports | Market Research | Scoop.it

Check for Discount on European Computerized Physician Order Entry Market report by MicroMarketMonitor. On purchase of this report, you get next three (3) quarterly...

Robert Mcmillian's insight:

Order report by calling ReportsnReports.com at +1 888 391 5441 OR send an email on sales@reportsandreports.com with (European Computerized Physician Order Entry Market) / report name in subject line and your contact details.

 

On purchase of this report, you get next three (3) quarterly updates of the report for free.

Computerized physician order entry (CPOE) is an efficient system that reduces the errors related to handwriting, and provides order entry at the point-of-care. CPOE is a process of electronically entering medical prescription and instruction during a treatment. The order entry is transmitted over a network to various departments within the hospital, including the pharmacy, laboratory, and radiology.
 
CPOE system is used extensively by the emergency healthcare service providers, hospitals, nurses, and office based physicians. The pharmaceutical industry is growing at a very fast pace in France, Germany, and Italy, which in-turn is driving the market for computerized physician order entry systems in Europe.
 
The CPOE market is segmented on the basis of types, component, deployment, application, end-users and geography.  Geographically the market is segmented into France, Germany, Italy, Spain, U.K., and Rest of Europe.

 

Complete report available @ http://www.reportsnreports.com/reports/313885-european-computerized-physician-order-entry-market.html .

Europe is the second-largest region in the global market for computerized physician order entry. This market is expected grow at a CAGR of 6.0%, from 2013 to 2018. It is projected to reach a value of $292.37 million by 2018. This market is driven by high incidences of wrong medication, which demands the adoption of computerized physician order entry systems in Europe. Furthermore, the high cost of the treatment drugs related injuries and the investments made by the European government are another reason for high adoption of the CPOE systems. However, the cost and time involved in the installation of computerized physician order entry systems is major factor restraining the growth of this market.
 
The key players in the European computerized physician order entry market are Allscripts (U.S.), Athenahealth (U.S.), Cerner Corporation (U.S.), Carestream Health Inc. (U.S.), eClinicalWorks LLC (U.S.), Epic Systems (U.S.), GE Healthcare (U.K.), McKesson Corporation (U.S.), Philips Healthcare (Netherlands), Practice Fusion (U.S.), and Siemens Healthcare AG (Germany).

Purchase a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=313885 .

Table of Contents

1 Introduction
1.1 Introduce the Market
1.2 Objective of the study
1.3 Market Definition and Scope of the study
1.3.1 Market Definition
1.3.2 Areas covered
1.3.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Secondary sources
1.5.2 Primary Sources
1.5.3 Market estimation methodology (Top-down, bottom-up, data triangulation.)
1.5.4 Macro indicators for the study
1.6 Assumptions
1.7 List of Acronyms

2 Market Overview

3 Computerized Physician Order Entry, By Applications
3.1 Computerized Physician Order Entry, Split By Geography
3.2 CPOE, Clinical Guidelines
3.2.1 Clinical Guidelines, By Geographies
3.2.1.1 United Kingdom-Clinical Guidelines
3.2.1.2 France-Clinical Guidelines
3.2.1.3 Germany-Clinical Guidelines

Inquire before buying this report on price $3500 @ http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=313885 .

 

About Us:

ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets. 

more...
No comment yet.
Scooped by Robert Mcmillian
Scoop.it!

North American CDSS (Knowledge-based/Evidence based) Industry Worth $283 million by 2018

North American CDSS (Knowledge-based/Evidence based) Industry Worth $283 million by 2018 | Market Research | Scoop.it

Check for Discount on North American Knowledge-based/Evidence based Clinical decision support systems (CDSS) Market report by MicroMarketMonitor. On purchase of this report, you get next three (3) quarterly...

Robert Mcmillian's insight:

Order report by calling ReportsnReports.com at +1 888 391 5441 OR send an email on sales@reportsandreports.com with (North American Knowledge-based/Evidence based Clinical decision support systems (CDSS) Market) / report name in subject line and your contact details.

 

On purchase of this report, you get next three (3) quarterly updates of the report for free.

The North American knowledge-based CDSS market was valued at $177 million in 2012, and expected to reach $283 million by 2018, at a CAGR of 7.8%.

The report ‘North American Knowledge-based CDSS Market forecast, 2012-2020’ analyzes the market by sub-segments integrated knowledge-based CDSS and standalone knowledge-based CDSS. Integrated CDSS accounted for about 70% of the total market. The North American knowledge-based CDSS market can also be segmented based upon components into hardware, software, and services.

North America is the global leader in the knowledge-based CDSS market due to advancement in technology and higher awareness rate amongst patients. North America is a huge market, accounting to almost 70% of the total market. The U.S. accounted for 90% of the total North American knowledge-based CDSS market.

The major driver for the North American knowledge-based CDSS market is the increasing demand for analytical IT solutions that help in point-of-care decision making. The implementation of such solutions has resulted into reduction of cost and improvement in the quality of care provided. Other factors responsible for the growth of the market are the increasing government initiatives and introduction of various incentive plans for healthcare providers.

 

Complete report available @ http://www.reportsnreports.com/reports/313718-north-american-knowledge-based-evidence-based-clinical-decision-support-systems-cdss-market.html .

 

The North American knowledge-based CDSS market report also provides an extensive competitive landscaping of companies operating in this market. Meditech is the North American knowledge-based CDSS market leader followed by major players like Cerner Corporation, Athenahealth, Inc., McKesson Corporation, and Zynx Health Incorporated.

Segment and country specific company shares, news & deals, mergers and acquisitions, segment specific pipeline products, product approvals, and product recalls of the major companies have been detailed in this report.

Customization Options

Along with the market data, you can also customize MMM assessments that meet your company’s specific needs. Customize to get comprehensive industry standard and deep dive analysis of the following parameters:

Product Analysis

Usage pattern (in-depth trend analysis) of products (segment wise)Product matrix which gives a detailed comparison of product portfolio of each company mapped at country and sub-segment levelEnd-user adoption rate analysis of the products (segment wise and country wise)

Procedure Volume Data

Number of software installedEnd-users

Surgeons/Physicians Perception Matrix

Fast turn-around analysis of surgeons response to market events and trendsPattern analysis of usage of devices by physiciansSurgeons’ opinion about products from different companies

Brand Perception Matrix

Comprehensive study of customers perception and behavior through our inbuilt social connect tool checking the virality and tonality of blogsAnalysis of overall brand usage and familiarity and brand advocacy distribution (detractor/neutral/familiar)

Alternative Products: Impact analysis

MMM’s healthcare decision making quadrant is an innovative and useful quadrant for vendors who wish to analyze the potential growth markets based on parameters like end-user dynamics (choices, number of installations of software) and macroeconomic indicators (number of hospitals, reimbursement scenario, diagnosis rate, treatment rate and healthcare expenditure).

 

Purchase a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=313718 .

 

Table of Contents

1 Introduction
1.1 Objective of the study
1.2 Market Definitions
1.3 Market Segmentation & Aspects Covered
1.4 Research Methodology
1.4.1 Assumptions (Market Size, Forecast, etc)

2 Executive Summary

3 Market Overview

4 Knowledge-based/Evidence based CDSS-North America, by Applications
4.1 Split by Geography
4.1 Knowledge-based/Evidence based CDSS-U.S. by Applications
4.1 Knowledge-based/Evidence based CDSS-Canada by Applications
4.1 Knowledge-based/Evidence based CDSS-Mexico by Applications
4.2 Knowledge-based/Evidence based CDSS-North America-Drug Allergy Alerts
4.2.1 Knowledge-based/Evidence based CDSS-North America-Drug Allergy Alerts, by Geographies
4.2.1.1 Knowledge-based/Evidence based CDSS-U.S.-Drug Allergy Alerts
4.2.1.2 Knowledge-based/Evidence based CDSS-Canada-Drug Allergy Alerts

Inquire for Discount on price $3500 @ http://www.reportsnreports.com/contacts/discount.aspx?name=313718 .

 

About Us:

ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets. 

more...
No comment yet.
Scooped by Robert Mcmillian
Scoop.it!

North American Cardiology PACS Industry Worth $276 million by 2018

North American Cardiology PACS Industry Worth $276 million by 2018 | Market Research | Scoop.it

Check for Discount on North American Cardiology PACS Market Research Report report by MicroMarketMonitor. On purchase of this report, you get next three (3) quarterly...

Robert Mcmillian's insight:

Order report by calling ReportsnReports.com at +1 888 391 5441 OR send an email on sales@reportsandreports.com with (North American Cardiology PACS Market Research Report) / report name in subject line and your contact details.

 

On purchase of this report, you get next three (3) quarterly updates of the report for free.

The North American cardiology picture archiving and communication system (PACS) market was valued at $193 million in 2012, and expected to grow at a CAGR of 6.10% to reach $276 million by 2018.

The report ‘North American Cardiology PACS Market forecast, 2012-2018’ analyzes the market based on components, delivery mode, imaging modality, and application type. In the delivery mode segment, on-premise forms the largest segment of the market, as it is perceived to offer secure sharing of data. North America leads the global market accounting to 48% of the market share. The U.S. holds 90% share in the North American market.

The cardiology picture archiving and communication system has helped in reducing the physical barriers associated with traditional film-based image retrieval, distribution, and display. The system has widespread application in hospitals and clinics, as it eliminates the need of maintaining hard copies of images and replaces them with digital copies. Cloud-based PACS solution is the latest market development expected to capture a significant market share in the next 5 years.

The cardiology picture archiving and communication system (PACS) market report also provides an extensive competitive landscaping of companies operating in this market. GE Healthcare (U.K.) is the market leader followed by major players like McKesson Corporation, Philips Healthcare (The Netherlands), Agfa HealthCare (Belgium), Siemens Healthcare (Germany), Carestream Health (U.S.), Fujifilm Corporation (Japan) and others.

Segment and country-specific company shares, news & deals, M&A, segment-specific pipeline products, product approvals, and product recalls of the major companies have been detailed in this report.

 

Complete report available @ http://www.reportsnreports.com/reports/313859-north-american-cardiology-pacs-market-research-report.html .

Customization Options

Along with the market data, you can also customize MMM assessments that meet your company’s specific needs. Customize to get comprehensive industry standard and deep dive analysis of the following parameters:

Product Analysis

Usage pattern (in-depth trend analysis) of products (segment-wise)Product matrix which gives a detailed comparison of product portfolio of each company mapped at country and sub-segment levelEnd-user adoption rate analysis of the products (segment-wise and country-wise)

Procedure Volume Data

Number of software installedEnd-users

Brand Perception Matrix

Comprehensive study of customers perception and behavior through our in-built social connect tool checking the virality and tonality of blogsAnalysis of overall brand usage and familiarity and brand advocacy distribution (detractor/neutral/familiar)

Alternative Products: Impact analysis

MMM’s healthcare decision making quadrant is an innovative and useful quadrant for vendors who wish to analyze the potential growth markets based on parameters like end-user dynamics (choices and number of installations of software) and macroeconomic indicators (number of hospitals, reimbursement scenario, diagnosis rate, treatment rate and healthcare expenditure).

 

Purchase a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=313859 .

Table of Contents

1 Introduction
1.1 Objective of the study
1.2 Market Definitions
1.3 Market Segmentation & Aspects Covered
1.4 Research Methodology
1.4.1 Assumptions (Market Size, Forecast, etc)

2 Executive Summary

3 Market Overview

Inquire for Discount on price $3500 @ http://www.reportsnreports.com/contacts/discount.aspx?name=313859 .

 

About Us:

ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets. 

more...
No comment yet.
Scooped by Robert Mcmillian
Scoop.it!

North American Orthopedic Accessories Industry Analysis

North American Orthopedic Accessories Industry Analysis | Market Research | Scoop.it

Check for Discount on North American Orthopedic Accessories Market Research Report report by MicroMarketMonitor. On purchase of this report, you get next three (3) quarterly...

Robert Mcmillian's insight:

                                                                                       

New Market Research Report on “North American Orthopedic Accessories Market Research Report” added to ReportsnReports.com.

 

On purchase of this report, you get next three (3) quarterly updates of the report for free.

The North American orthopedic accessories systems market is mainly driven by aging population and the increasing prevalence of rheumatoid and osteoarthritis.

The report analyzes the market of devices in terms of 3 segments, namely, bone cement systems, removal systems, and casting system. All these segments experienced a positive growth till 2012, owing to an increased awareness for procedures and sophisticated diagnostic techniques. The increase in usage of orthopedic surgical process and trauma related injuries is the major driver for this market. The use of bone cement in spinal and joint replacement surgeries are increasing in popularity as the ideal material to fuse the artificial implant to the bone and thus, the market is expected to grow with the growth of these surgical processes.

The procedure volume growth is significantly higher in the U.S. and Mexico, as a result of fast disease progression, higher prevalence, improving healthcare infrastructure, economic growth, broadening insurance coverage, expanding private healthcare sector, and the increasing awareness amongst people. In North America (US, Canada), the rising rates of obese population have been driving the procedure growth but the extensive efforts to cut healthcare costs, thereby decreasing the reimbursements, will compel patients to opt for alternative surgeries such as arthroscopic debridement and MIS.

 Complete report available @ http://www.reportsnreports.com/reports/313698-north-american-orthopedic-accessories-market-research-report.html .

The prevalence of osteoarthritis in North America is around 8-10% in the adult population. The high prevalence in North America is because of high prevalence of diabetes and obese population.

The report also provides an extensive competitive landscaping of the leading companies operating in this market. The main companies operating in the market and extensively covered in this report are Biomet, DePuy, Stryker, and Smith & Nephew.

Customization Options:

Along with the market data, customize the MMM assessments to meet your company’s specific needs. Customize to get a comprehensive summary of the industry standards and a deep dive analysis of the following parameters:

Product Analysis:

Usage pattern (in-depth trend analysis) of products (segment-wise)Product matrix, which gives a detailed comparison of product portfolio of each company, mapped at country and sub-segment levelsApplications of the products (segment-wise and country-wise)A comprehensive coverage of product approvals, pipeline products, and product recalls

Epidemiology Data:

Country-specific incidence of trauma cases

Procedure Volume Data:

Orthopedic surgical process and trauma-related procedures performed annually in each country, tracked till sub-segment levelThe number of spinal and joint replacement surgeries performed in each country

Surgeons/Physicians Perception Analysis:

Fast turn-around analysis of surgeons’ responses to market events and trendsPattern analysis of usage of bone cements (antibiotic and non-antibiotic) by physiciansSurgeons’ opinions about products from different companiesSurgeons’ qualitative inputs on epidemiology data

Brand/Product Perception Matrix:

A comprehensive study of customers’ perception and behavior through our inbuilt social connect tool checking the virality and tonality of blogsAn analysis of overall brand usage and familiarity and brand advocacy distribution (Detractor/Neutral/Familiar)

Alternative Products: Impact analysis

MMM’s Healthcare Decision Making Quadrant: It is an innovative and useful quadrant for vendors who wish to analyze the potential growth markets based on parameters such as patient dynamics (patient pool, epidemiology of disease, preference towards surgeries/alternative therapies) and macroeconomic indicators (number of hospitals and orthopedic clinics, reimbursement scenario, diagnosis rate, treatment rate and healthcare expenditure)

 

Purchase a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=313698 .

Table of Contents

1 Introduction
1.1 Objective of the study
1.2 Market Definitions
1.3 Market Segmentation & Aspects Covered
1.4 Research Methodology
1.4.1 Assumptions (Market Size, Forecast, etc)

2 Executive Summary

3 Market Overview

4 Orthopedic Accessories-North America, By Endusers
4.1 Split By Geography
4.1 Orthopedic Accessories-U.S. by Endusers
4.1 Orthopedic Accessories-Canada by Endusers
4.1 Orthopedic Accessories-Mexico by Endusers
4.2 Orthopedic Accessories-North America-Hospitals
4.2.1 Orthopedic Accessories-North America-Hospitals, By Geographies
4.2.1.1 Orthopedic Accessories-U.S.-Hospitals
4.2.1.2 Orthopedic Accessories-Canada-Hospitals

Inquire for Discount on price $3500 @ http://www.reportsnreports.com/contacts/discount.aspx?name=313698 .

About Us:

ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets. 

more...
No comment yet.
Scooped by Robert Mcmillian
Scoop.it!

Prosensa Therapeutics B.V. – Product Pipeline Review – 2014

Prosensa Therapeutics B.V. – Product Pipeline Review – 2014 | Market Research | Scoop.it
Prosensa Therapeutics B.V. - Product Pipeline Review - 2014 is a market research report available at US $1500 for a Single User PDF License from RnR Market Research Reports Library.
Robert Mcmillian's insight:

The report “Prosensa Therapeutics B.V. – Product Pipeline Review – 2014” is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with report name in subject line and your contact details to purchase this report or get your questions answered.

Summary

Researcher’s,‘Prosensa Therapeutics B.V. – Product Pipeline Review – 2014′, provides an overview of the Prosensa Therapeutics B.V.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Prosensa Therapeutics B.V.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Researcher’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Researcher’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Researcher’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Complete report is available @ http://www.rnrmarketresearch.com/prosensa-therapeutics-b-v-product-pipeline-review-2014-market-report.html .

Scope

- The report provides brief overview of Prosensa Therapeutics B.V. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Prosensa Therapeutics B.V.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Prosensa Therapeutics B.V.’s pipeline products

Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=235067 .

Reasons to Buy

- Evaluate Prosensa Therapeutics B.V.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Prosensa Therapeutics B.V. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Prosensa Therapeutics B.V.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Prosensa Therapeutics B.V. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Prosensa Therapeutics B.V.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Prosensa Therapeutics B.V. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 

Inquire before buying this report @ http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=235067 . (Single User License : US$ 1500 And Corporate User License : US$ 4500)

For further information on “Prosensa Therapeutics B.V. – Product Pipeline Review – 2014” report OR for any other business research / market intelligence need contact sales@rnrmarketresearch.com  / Call +1 888 391 5441.

more...
No comment yet.
Scooped by Robert Mcmillian
Scoop.it!

Colby Pharmaceutical Company – Product Pipeline Review – 2014

Colby Pharmaceutical Company – Product Pipeline Review – 2014 | Market Research | Scoop.it

Colby Pharmaceutical Company - Product Pipeline Review - 2014 is a market research report available at US $1500 for a Single User PDF License from RnR Market Research Reports Library.

Robert Mcmillian's insight:

The report “Colby Pharmaceutical Company – Product Pipeline Review – 2014” is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with report name in subject line and your contact details to purchase this report or get your questions answered.

Summary

Researcher’s, Colby Pharmaceutical Company – Product Pipeline Review – 2014′, provides an overview of the Colby Pharmaceutical Company’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Colby Pharmaceutical Company’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Researcher’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Researcher’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Researcher’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Complete report is available @ http://www.rnrmarketresearch.com/colby-pharmaceutical-company-product-pipeline-review-2014-market-report.html .

Scope

- The report provides brief overview of Colby Pharmaceutical Company including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Colby Pharmaceutical Company’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Colby Pharmaceutical Company’s pipeline products

Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=235065 .

Reasons to Buy

- Evaluate Colby Pharmaceutical Company’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Colby Pharmaceutical Company in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Colby Pharmaceutical Company’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Colby Pharmaceutical Company and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Colby Pharmaceutical Company
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Colby Pharmaceutical Company and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 

Inquire before buying this report @ http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=235065 . (Single User License : US$ 1500 And Corporate User License : US$ 4500)

For further information on “Colby Pharmaceutical Company – Product Pipeline Review – 2014” report OR for any other business research / market intelligence need contact sales@rnrmarketresearch.com  / Call +1 888 391 5441.

more...
No comment yet.
Scooped by Robert Mcmillian
Scoop.it!

Enterocolitis Therapeutics Industry Pipeline Review, H2 2014

Enterocolitis Therapeutics Industry Pipeline Review, H2 2014 | Market Research | Scoop.it

Enterocolitis - Pipeline Review, H2 2014 is a market research report available at US $2000 for a Single User PDF License from RnR Market Research Reports Library.

Robert Mcmillian's insight:

The report “Enterocolitis – Pipeline Review, H2 2014” is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with report name in subject line and your contact details to purchase this report or get your questions answered.

Summary

Researcher’s, Enterocolitis – Pipeline Review, H2 2014′, provides an overview of the Enterocolitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Enterocolitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Enterocolitis and special features on late-stage and discontinued projects.

Researcher’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Researcher’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Researcher’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Complete report is available @ http://www.rnrmarketresearch.com/enterocolitis-pipeline-review-h2-2014-market-report.html .

Scope

- The report provides a snapshot of the global therapeutic landscape of Enterocolitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Enterocolitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Enterocolitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Enterocolitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=235040 .

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Enterocolitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Enterocolitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Inquire before buying this report @ http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=235040 . (Single User License : US$ 2000 And Corporate User License : US$ 6000)

For further information on “Enterocolitis – Pipeline Review, H2 2014” report OR for any other business research / market intelligence need contact sales@rnrmarketresearch.com  / Call +1 888 391 5441.

more...
No comment yet.
Scooped by Robert Mcmillian
Scoop.it!

Multiple Myeloma (Kahler’s Disease) Therapeutics Industry Pipeline Review, H2 2014

Multiple Myeloma (Kahler’s Disease) Therapeutics Industry Pipeline Review, H2 2014 | Market Research | Scoop.it

Multiple Myeloma (Kahler's Disease) - Pipeline Review, H2 2014 is a market research report available at US $2000 for a Single User PDF License from RnR Market Research Reports Library.

Robert Mcmillian's insight:

The report “Multiple Myeloma (Kahler’s Disease) – Pipeline Review, H2 2014” is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with report name in subject line and your contact details to purchase this report or get your questions answered.

Summary

Researcher’s, ‘Multiple Myeloma (Kahler’s Disease) – Pipeline Review, H2 2014′, provides an overview of the Multiple Myeloma (Kahler’s Disease)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler’s Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler’s Disease) and special features on late-stage and discontinued projects.

Multiple myeloma is diagnosed with blood tests (serum protein electrophoresis, serum free kappa/lambda light chain assay), bone marrow examination, urine protein electrophoresis, and X-rays of commonly involved bones.

Multiple myeloma is considered to be incurable but treatable. Remissions may be induced with steroids, chemotherapy, proteasome inhibitors, immunomodulatory drugs such as thalidomide or lenalidomide, and stem cell transplants. Radiation therapy is sometimes used to reduce pain from bone lesions.

Researcher’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Researcher’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Researcher’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Complete report is available @ http://www.rnrmarketresearch.com/multiple-myeloma-kahlers-disease-pipeline-review-h2-2014-market-report.html .

Scope

- The report provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler’s Disease)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Multiple Myeloma (Kahler’s Disease) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Multiple Myeloma (Kahler’s Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Multiple Myeloma (Kahler’s Disease) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=235014 .

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Multiple Myeloma (Kahler’s Disease)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler’s Disease) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Inquire before buying this report @ http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=235014 . (Single User License : US$ 2000 And Corporate User License : US$ 6000)

For further information on “Multiple Myeloma (Kahler’s Disease) – Pipeline Review, H2 2014” report OR for any other business research / market intelligence need contact sales@rnrmarketresearch.com  / Call +1 888 391 5441.

more...
No comment yet.
Scooped by Robert Mcmillian
Scoop.it!

Overactive Bladder Therapeutics Industry Pipeline Review, H2 2014

Overactive Bladder Therapeutics Industry Pipeline Review, H2 2014 | Market Research | Scoop.it

Overactive Bladder - Pipeline Review, H2 2014 is a market research report available at US $2000 for a Single User PDF License from RnR Market Research Reports Library.

Robert Mcmillian's insight:

The report “Overactive Bladder – Pipeline Review, H2 2014” is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with report name in subject line and your contact details to purchase this report or get your questions answered.

Summary

Researcher’s, Overactive Bladder Pipeline Review, H2 2014′, provides an overview of the Overactive Bladder’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Overactive Bladder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Overactive Bladder and special features on late-stage and discontinued projects.

Researcher’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Researcher’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Researcher’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Management of overactive bladder is addressed in terms of quality of life since it is not a life-threatening problem, and treatment is not always necessary if the treatment would cause more discomfort than the symptoms. The person often keeps a diary tracking urination to help determine whether treatments are working. If the person's quality of life is impaired and behavioral therapies do not work, medications such as anti-muscarinic drugs are used to control the symptoms. Invasive treatment such as surgery to modify spinal nerves is possible but is avoided because of the potential for permanent damage and the nonthreatening nature of the disorder. Overactive bladder is not rare, estimates in population studies vary widely and suggest that from 7-27% of men and 9-43% of women experience these symptoms.[citation needed] Other studies suggest that the condition is more common in men.[citation needed] Many people who have problems have them for less than a year.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report is available @ http://www.rnrmarketresearch.com/overactive-bladder-pipeline-review-h2-2014-market-report.html .

Scope

The report provides a snapshot of the global therapeutic landscape of Overactive BladderThe report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activitiesThe report reviews key players involved in the therapeutics development for Overactive Bladder and enlists all their major and minor projectsThe report summarizes all the dormant and discontinued pipeline projectsA review of the Overactive Bladder products under development by companies and universities/research institutes based on information derived from company and industry-specific sourcesPipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stagesA detailed assessment of monotherapy and combination therapy pipeline projectsCoverage of the Overactive Bladder pipeline on the basis of target, MoA, route of administration and molecule typeLatest news and deals relating related to pipeline products

Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=235010 .

Reasons to Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantageDevelop strategic initiatives by understanding the focus areas of leading companiesIdentify and understand important and diverse types of therapeutics under development for Overactive BladderPlan mergers and acquisitions effectively by identifying key players of the most promising pipelineDevise corrective measures for pipeline projects by understanding Overactive Bladder pipeline depth and focus of Indication therapeuticsDevelop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeModify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Inquire before buying this report @ http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=235010 . (Single User License : US$ 2000 And Corporate User License : US$ 6000)

For further information on “Overactive Bladder – Pipeline Review, H2 2014” report OR for any other business research / market intelligence need contact sales@rnrmarketresearch.com  / Call +1 888 391 5441.

more...
No comment yet.
Scooped by Robert Mcmillian
Scoop.it!

Venous Leg Ulcers (Crural ulcer) Therapeutics – Pipeline Market Review, H2 2014

Venous Leg Ulcers (Crural ulcer) Therapeutics – Pipeline Market Review, H2 2014 | Market Research | Scoop.it

Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2014 is a market research report available at US $2000 for a Single User PDF License from RnR Market Research Reports Library.

Robert Mcmillian's insight:

The report “Venous Leg Ulcers (Crural ulcer) – Pipeline Review, H2 2014” is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with report name in subject line and your contact details to purchase this report or get your questions answered.

Summary

Researcher’s, ‘Venous Leg Ulcers (Crural ulcer) Pipeline Review, H2 2014′, provides an overview of the Venous Leg Ulcers (Crural ulcer)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Venous Leg Ulcers (Crural ulcer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Leg Ulcers (Crural ulcer) and special features on late-stage and discontinued projects.

Researcher’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Researcher’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Researcher’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report is available @ http://www.rnrmarketresearch.com/venous-leg-ulcers-crural-ulcer-pipeline-review-h2-2014-market-report.html .

Scope

The report provides a snapshot of the global therapeutic landscape of Venous Leg Ulcers (Crural ulcer)The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activitiesThe report reviews key players involved in the therapeutics development for Venous Leg Ulcers (Crural ulcer) and enlists all their major and minor projectsThe report summarizes all the dormant and discontinued pipeline projectsA review of the Venous Leg Ulcers (Crural ulcer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sourcesPipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stagesA detailed assessment of monotherapy and combination therapy pipeline projectsCoverage of the Venous Leg Ulcers (Crural ulcer) pipeline on the basis of target, MoA, route of administration and molecule typeLatest news and deals relating related to pipeline products

Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=201683 .

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantageDevelop strategic initiatives by understanding the focus areas of leading companiesIdentify and understand important and diverse types of therapeutics under development for Venous Leg Ulcers (Crural ulcer)Plan mergers and acquisitions effectively by identifying key players of the most promising pipelineDevise corrective measures for pipeline projects by understanding Venous Leg Ulcers (Crural ulcer) pipeline depth and focus of Indication therapeuticsDevelop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeModify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Inquire before buying this report @ http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=201683 . (Single User License : US$ 2000 And Corporate User License : US$ 6000)

For further information on “Venous Leg Ulcers (Crural ulcer) – Pipeline Review, H2 2014” report OR for any other business research / market intelligence need contact sales@rnrmarketresearch.com  / Call +1 888 391 5441.

more...
No comment yet.
Scooped by Robert Mcmillian
Scoop.it!

Small-Cell Lung Cancer Disease Pipeline Industry Review, H2 2014

Small-Cell Lung Cancer Disease Pipeline Industry Review, H2 2014 | Market Research | Scoop.it
Small-Cell Lung Cancer - Pipeline Review, H2 2014 is a market research report available at US $2000 for a Single User PDF License from RnR Market Research Reports Library.
Robert Mcmillian's insight:

The report “Small-Cell Lung Cancer – Pipeline Review, H2 2014” is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with report name in subject line and your contact details to purchase this report or get your questions answered.

Summary

Researcher’s,‘Small-Cell Lung Cancer Pipeline Review, H2 2014′, provides an overview of the Small-Cell Lung Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects.

Researcher’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Researcher’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Researcher’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Complete report is available @ http://www.rnrmarketresearch.com/small-cell-lung-cancer-pipeline-review-h2-2014-market-report.html .

Scope

The report provides a snapshot of the global therapeutic landscape of Small-Cell Lung CancerThe report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activitiesThe report reviews key players involved in the therapeutics development for Small-Cell Lung Cancer and enlists all their major and minor projectsThe report summarizes all the dormant and discontinued pipeline projectsA review of the Small-Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sourcesPipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stagesA detailed assessment of monotherapy and combination therapy pipeline projectsCoverage of the Small-Cell Lung Cancer pipeline on the basis of target, MoA, route of administration and molecule typeLatest news and deals relating related to pipeline products

Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=206565 .

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantageDevelop strategic initiatives by understanding the focus areas of leading companiesIdentify and understand important and diverse types of therapeutics under development for Small-Cell Lung CancerPlan mergers and acquisitions effectively by identifying key players of the most promising pipelineDevise corrective measures for pipeline projects by understanding Small-Cell Lung Cancer pipeline depth and focus of Indication therapeuticsDevelop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeModify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Inquire before buying this report @ http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=206565  . (Single User License : US$ 2000 And Corporate User License : US$ 6000)

For further information on “Small-Cell Lung Cancer – Pipeline Review, H2 2014” report OR for any other business research / market intelligence need contact sales@rnrmarketresearch.com  / Call +1 888 391 5441.

more...
No comment yet.
Scooped by Robert Mcmillian
Scoop.it!

Mexico Hyperbaric Oxygen Chambers Industry Analysis and Forecast to 202

Mexico Hyperbaric Oxygen Chambers Industry Analysis and Forecast to 202 | Market Research | Scoop.it

Mexico Hyperbaric Oxygen Chambers Market Outlook to 2020 is a market research report available at US $2500 for a Single User PDF License from RnR Market Research Reports Library.

Robert Mcmillian's insight:

The report “Mexico Hyperbaric Oxygen Chambers Market Outlook to 2020” is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with report name in subject line and your contact details to purchase this report or get your questions answered.

Summary

Researcher’s new report, “Mexico Hyperbaric Oxygen Chambers Market Outlook to 2020″, provides key market data on the Mexico Hyperbaric Oxygen Chambers market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments Hyperbaric Oxygen Chambers (Monoplace and Multiplace Hyperbaric Oxygen Chambers).

The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Hyperbaric Oxygen Chambers market wherever available.

The data in the report is derived from dynamic market forecast models. Researcher uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible.

The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers.

Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases).

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Complete report is available @ http://www.rnrmarketresearch.com/mexico-hyperbaric-oxygen-chambers-market-outlook-to-2020-market-report.html .

Scope

Market size data for Hyperbaric Oxygen Chambers market segments Hyperbaric Oxygen Chambers.Annualized market revenues (USD million), volume (units) and average prices (in US dollars) data for each of the market segments. Data is provided from 2005 to 2013 and forecast to 2020.2013 company shares and distribution shares data for Hyperbaric Oxygen Chambers market.Global corporate-level profiles of key companies operating within the Mexico Hyperbaric Oxygen Chambers.Key players covered include Repuestos Para Maquinaria Industrial, S.A.Remisa, Partupa and Hyperbaric Chambers Del Valle S.A. de C.V.

Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=233890 .

Reasons to buy

Develop business strategies by identifying the key market categories and segments poised for strong growth in the future.Develop market-entry and market expansion strategies.Design competition strategies by identifying who-stands-where in the market.Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.What are the key distribution channels and what’s the most preferred mode of product distribution Identify, understand and capitalize.

 

Inquire for Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=233890 . (Single User License : US$ 2500 And Corporate User License : US$ 7500)

For further information on “Mexico Hyperbaric Oxygen Chambers Market Outlook to 2020” report OR for any other business research / market intelligence need contact sales@rnrmarketresearch.com  / Call +1 888 391 5441.

more...
No comment yet.